TACE promotes TREM2+ TAMs, which suppress CD8+ T cells and contribute to HCC progression. TREM2 deficiency enhances CD8+ T cell activity and improves anti-PD-L1 therapy, making TREM2 a potential immunotherapy target post-TACE. This evidence concerns the gene CD8A and hepatocellular carcinoma.